Determinants of interleukin-6 and C-reactive protein vary in polycystic ovary syndrome, as do effects of short- and long-term metformin therapy

Hormone Research

Volumn 71, Issue 3, 2009, Pages 148-154

  Tsilchorozidou, Tasoula ^a   Mohamed Ali, Vidya ^b   Conway, Gerard S ^a,c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

C reactive protein; Cytokines; Interleukin 6; Metformin; Polycystic ovary syndrome

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; METFORMIN;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; NAUSEA; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SHORT COURSE THERAPY; STOMACH PAIN; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADIPOSITY; ADULT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERLEUKIN-6; MENSTRUAL CYCLE; METFORMIN; POLYCYSTIC OVARY SYNDROME; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 59749098210     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000197871     Document Type: Article

References (54)

1. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41:1257-1266.
2. Franks S: Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
3. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
4. Rebuffe-Scrive M, Cullberg G, Lundberg PA, Lindstedt G, Bjorntorp P: Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 1989;21:391-397.
5. Holte J, Bergh T, Berne C, Berglund L, Lithell H: Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metabol 1994;78:1052-1058.
6. Talbott E, Guzick D, Clerisi A, Berga S, Detre K, Weimer K, Kuller L: Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821-826.
7. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, Mattson LA, Crona N, Lundberg PA: Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992;57:505-513.
8. Dunaif A: Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995;16:98:33S-39S.
9. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS: Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995;96:520-527.
10. Colilla S, Cox NJ, Ehrmann DA: Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001;86:2027-2031.
11. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-674.
12. Mendall NA: C-reactive protein response and progression of atherosclerosis: is atherosclerosis the byproduct of systemic infection? Cardiologia 1997;42:1139-1144.
13. Pradhan AD, Skerrett PJ, Manson JE: Obesity, diabetes, and coronary risk in women. J Cardiovasc Risk 2002;9:323-330.
14. Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Rantanen T, Pyorala K: CRP, fibrinogen, IL-6 and TNF-a in the prognostic classification of unstable angina pectoris. Ann Med 2001;33:37-47.
15. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B: Elevated levels of IL-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338-3342.
16. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B: Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002;87:2084-2089.
17. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and IL-6 expression in human obesity and insulin resistance. Am J Physiol 2001;280:E745-E751.
18. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE: Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obesity Res 2001;9:414.
19. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N: Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-2455.
20. Fenki V, Fenkci S, Yilmazer M, Serteser M: Decreased total antioxidant status and increased oxidative stress in women with PCOS may contribute to the cardiovascular disease. Fertil Steril 2003;80:123-127.
21. Boulman Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z: Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89:2160-2165.
22. Tarkum I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C: Endothelial dysfunction in young women with PCOS: relationship with insulin resistance and low-grade inflammation. J Clin Endocrinol Metab 2004;89:5592-5596.
23. Diamanti-Kandaraki E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D: Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21:1426-1431.
24. Escobar-Morreale HF, Villuendas JR, Botella-Carretero JI, Sancho J, San Millan JL: Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk marker in pre-menopausal women. Diabetologia 2003;46:625-633.
25. Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AFH, Schill T, Schlosser HW, Brabant AG, Schoff C: The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004;150:525-532.
26. Taponen S, Martikainen H, Järvelin MR, Sovio U, Laitinen J, Pouta A, Hartikainen AL, McCarthy MI, Franks S, Paldanius M, Ruokonen A: Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol and Metab 2004;89:2114-2118.
27. Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker T, Bellastella A, Carella C, Izzo A: Serum and follicular fluid cytokines in PCOS during stimulated cycles. Obstet Gynecol 2003;101:1177-1182.
28. Ibanez L, Zegher F: Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004;89:1592-1597.
29. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM: Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-2774.
30. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999;48:511-519.
31. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS: A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;82:421-429.
32. Tsilchorozidou T, Honour JW, Conway GS: Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. Clin Endocrinol Metab 2003;88:5907-5913.
33. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-3672.
34. Greenspan FS, Strewler GJ: Basic and Clinical Endocrinology, ed 5. Stamford, Appleton & Lange, 1997, p 483.
35. Dunn JF, Nisula BC, Rodbard D: Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981;53:58-68.
36. Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstand S, Hougaard DM, Richelsen B: Weight loss larger than 10% is needed for the general improvement of circulating adipokine and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008;158:179-187.
37. Wiernsperger NF, Bailey CJ: The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999;58(suppl 1):31-39; discussion 75-82.
38. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
39. McCarthy MF: AMPK activation may suppress hepatic production of C-reactive protein by stimulating nitric oxide synthase. Med Hypotheses 2004;63:328-333.
40. Davis BJ, Xie Z, Viollet B, Zou MH: Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006;55:496-505.
41. Towler MC, Hardie DG: AMP-activated protein kinase in metabolic control and insulin signalling. Circ Res 2007;16 100:328-341.
42. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. New Engl J Med 1995;31:550-554.
43. Golay A: Metformin and body weight. Int J Obes 2008;32:61-72.
44. Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G, Azziz R, Colao A: Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005;90:6072-6076.
45. Ibáñez L, de Zegher F: Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab 2005;90:39-43.
46. Orio F, Manguso F, Di Biase S, Falbo A, Giallauria F, Labella D, Tolino A, Lombardi G, Colao A, Palomba S: Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur J Endocrinol 2007;157:69-73.
47. Velijia-Asimi Z: C-reactive protein in obese PCOS women and the effect of metformin therapy. Bosn J Basic Med Sci 2007;7:90-93.
48. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E, Diabetes Prevention Program Research Group: Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005;54:1566-1572.
49. Carter AM, Bennett CE, Bostock JA, Grant PJ: Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with type 2 diabetes mellitus. Diabetes Med 2005;22:1282-1284.
50. Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, Nam M, Chung CH, Lee KW, Nam CM, Lee HC: Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007;66:282-289.
51. Freemark M, Bursey D: The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:E55.
52. Bulcão C, Ribeiro-Filho FF, Sañudo A, Roberta Ferreira SG: Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs 2007;7:219-224.
53. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schönbeck U, Libby P: Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006;26:611-617.
54. Hattori Y, Suzuki K, Hattori S, Kasai K: Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006;47:1183-1188.